🔴 Veru is trading 5% down in after-hours trading after Q3 loss and effectively zero revenue

Veru is trading 5.05% down at $2.63 after fiscal third-quarter results showed a $0.30-per-share loss and effectively zero revenue.

• The loss modestly beat expectations, but the company remains unprofitable and focused on clinical development.
• PLATEAU enrollment reached 239 patients, with interim results expected in Q1 2027.
• Shares rallied 18.88% in regular trading to $2.77 before declining, suggesting profit-taking or disappointment.